Inventor
MICHAEL C. JENSEN
Inventor
US
Overview
Patents· 29 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides24%
A61KPreparations for medical, dental or toiletry purposes23%
C12NMicroorganisms or enzymes20%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations18%
G01NInvestigating or analysing materials by determining their chemical or physical properties8%
C12YEnzymes7%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
12,570,716Anti-dinitrophenol chimeric antigen receptors202612,503,507Defined composition gene modified T-cell products202512,448,445Transgene genetic tags and methods of use202512,421,294Truncated epiderimal growth factor receptor (EGFRt) for transduced t cell selection202512,312,416Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors202512,269,862Methods of use for CAR T cells202512,258,397Production of engineered T-cells by sleeping beauty transposon coupled with methotrexate selection202512,240,870Sequencing method for CAR T cell therapy202512,233,090Bispecific or-gate chimeric antigen receptor responsive to CD20 and CD19202512,226,435Bispecific OR-gate chimeric antigen receptor responsive to CD20 and CD19202512,202,897Drug regulated transgene expression202512,180,457Closed-system manufacturing process for CAR-T cells202412,173,071Methods and compositions comprising B7H3 chimeric antigen receptors202412,152,079Nucleic acids encoding IL-13 receptor alpha 2 (IL13Ra2) chimeric antigen receptor for tumor specific T cell immunotherapy202412,098,208Early intervention methods to prevent or ameliorate toxicity202412,053,491Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20202411,851,649Generating mammalian T cell activation inducible synthetic promoters (SYN+PRO) to improve T cell therapy202311,826,384Genetic engineering of macrophages for immunotherapy202311,779,602Methods of use for CAR T cells202311,760,804Early intervention methods to prevent or ameliorate toxicity202311,649,288Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents202311,458,167Bispecific CAR T-cells for solid tumor targeting202211,414,486Transgene genetic tags and methods of use202211,408,005Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells202211,311,576Methods of use for CAR T cells202211,253,546Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20202211,160,833Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20202111,155,616Drug regulated transgene expression202111,155,783Truncated epiderimal growth factor receptor (EGFRt) for transduced T cell selection2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2026Patents assigned to SEATTLE CHILDRENS HOSPITAL (27)· patent assignee history
2021–2025Patents assigned to UNIV CALIFORNIA (5)· patent assignee history
2021–2025Patents assigned to HOPE CITY (2)· patent assignee history
2021–2026Based in US· patent location history
2023–2025Patents assigned to ENDOCYTE INC (3)· patent assignee history
2023–2025Patents assigned to PURDUE RESEARCH FOUNDATION (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SEATTLE CHILDRENS HOSPITAL | 27 | 2021–2026 |
| UNIV CALIFORNIA | 5 | 2021–2025 |
| ENDOCYTE INC | 3 | 2023–2025 |
| PURDUE RESEARCH FOUNDATION | 3 | 2023–2025 |
| HOPE CITY | 2 | 2021–2025 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 29 | 2021–2026 |